Handelsbanken Fonder AB Acquires Shares of 15,900 Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Handelsbanken Fonder AB acquired a new stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 15,900 shares of the biotechnology company’s stock, valued at approximately $228,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Pacer Advisors Inc. grew its holdings in Atara Biotherapeutics by 50.9% during the 1st quarter. Pacer Advisors Inc. now owns 4,608 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 1,554 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Atara Biotherapeutics by 294.3% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 27,600 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 20,600 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Atara Biotherapeutics by 8.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 905,344 shares of the biotechnology company’s stock valued at $17,775,000 after buying an additional 73,462 shares in the last quarter. Norges Bank purchased a new stake in Atara Biotherapeutics during the 4th quarter valued at approximately $26,642,000. Finally, UBS Asset Management Americas Inc. grew its holdings in Atara Biotherapeutics by 33.6% during the 4th quarter. UBS Asset Management Americas Inc. now owns 80,818 shares of the biotechnology company’s stock valued at $1,586,000 after buying an additional 20,335 shares in the last quarter.

A number of research firms recently weighed in on ATRA. JPMorgan Chase & Co. raised shares of Atara Biotherapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $23.00 to $29.00 in a report on Thursday. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research note on Tuesday, March 2nd. HC Wainwright decreased their target price on Atara Biotherapeutics from $32.00 to $31.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Citigroup upgraded Atara Biotherapeutics from a “neutral” rating to a “buy” rating and set a $27.00 target price for the company in a research report on Tuesday, March 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $34.33.

In other news, COO Joe Newell sold 7,000 shares of the business’s stock in a transaction dated Monday, March 15th. The stock was sold at an average price of $17.41, for a total transaction of $121,870.00. Following the sale, the chief operating officer now owns 145,219 shares in the company, valued at $2,528,262.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Utpal Koppikar sold 1,761 shares of the company’s stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $14.58, for a total value of $25,675.38. Following the completion of the sale, the chief financial officer now owns 172,582 shares in the company, valued at approximately $2,516,245.56. The disclosure for this sale can be found here. Insiders have sold 11,401 shares of company stock worth $186,037 in the last 90 days. Insiders own 4.30% of the company’s stock.

Shares of ATRA stock opened at $14.99 on Friday. Atara Biotherapeutics, Inc. has a fifty-two week low of $8.90 and a fifty-two week high of $28.20. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -3.24 and a beta of 2.65. The stock’s 50-day simple moving average is $14.06 and its 200-day simple moving average is $17.80.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, May 3rd. The biotechnology company reported ($0.86) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.06. As a group, equities analysts expect that Atara Biotherapeutics, Inc. will post -3.89 earnings per share for the current year.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: Float

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.